Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.45 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16325412 | 1.00 | MDM2 (0.52) | MDM2CA1CA2TLR2TLR1 | |
| SCHEMBL29423558 | 0.93 | MDM2 (0.46) | MDM2CA1CA2TLR2TLR1 | |
| SCHEMBL16424792 | 0.93 | MDM2 (0.46) | MDM2CA1CA2TLR2TLR1 | |
| SCHEMBL22690415 | 0.93 | MDM2 (0.46) | MDM2CA1CA2TLR2TLR1 | |
| SCHEMBL22690416 | 0.93 | MDM2 (0.46) | MDM2CA1CA2TLR2TLR1 | |
| SCHEMBL30731420 | 0.93 | MDM2 (0.46) | MDM2CA1CA2TLR2TLR1 | |
| SCHEMBL4887094 | 0.92 | MDM2 (0.53) | MDM2CA1CA2TLR2TLR1 | |
| SCHEMBL4846913 | 0.92 | MDM2 (0.53) | MDM2CA1CA2TLR2TLR1 | |
| SCHEMBL31727174 | 0.91 | MDM2 (0.45) | MDM2CA1CA2TLR2TLR1 | |
| SCHEMBL17550375 | 0.90 | MDM2 (0.44) | MDM2CA1CA2TLR2TLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100092496-A1 | CHEMICAL LINKERS AND CONJUGATES THEREOF | MEDAREX, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-7691962-B2 | Chemical linkers and conjugates thereof | MEDAREX, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20080279868-A1 | Antibody-Drug Conjugates and Methods of Use | MEDAREX, INC. (US) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080279868-A1 | Antibody-Drug Conjugates and Methods of Use | CD47, ANTXR2, CD2BP2 | MDM2 3295/4885CA1 2106/4885CA2 4004/4885 |
| US-20100092496-A1 | CHEMICAL LINKERS AND CONJUGATES THEREOF | CLSPN, CD74, ANTXR2 | MDM2 1864/4885CA1 1175/4885CA2 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.